

Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant

Adeel A. Butt,^{1,2,3,*} Soha R. Dargham,⁴ Srusvin Loka,¹ Riyazuddin M. Shaik,¹ Hiam Chemaitelly,^{3,4} Patrick Tang,⁵ Mohammad R. Hasan,⁵ Peter V. Coyle,¹ Hadi M. Yassine,^{6,7} Hebah A. Al-Khatib,^{6,7} Maria K. Smatti,^{6,7} Anvar H. Kaleeckal,¹ Ali Nizar Latif,¹ Ahmed Zaqout,¹ Muna A. Almaslamani,¹ Abdullatif Al Khal,¹ Roberto Bertollini,⁸ Abdul-Badi Abou-Samra,¹ and Laith J. Abu-Raddad^{3,4,9}

¹Hamad Medical Corporation, Doha, Qatar; ²Department of Medicine, Weill Cornell Medicine, New York, New York and Doha, Qatar; ³Department of Population Health Sciences, Weill Cornell Medicine, New York, New York and Doha, Qatar; ⁴Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar; ⁵Sidra Medicine, Doha, Qatar; ⁶Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar; ⁷Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar; ⁸Ministry of Public Health Qatar, Doha, Qatar; and ⁹Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar

Background. There are limited data assessing coronavirus 2019 (COVID-19) disease severity in children/adolescents infected with the Omicron variant.

Methods. We identified children and adolescents <18 years of age with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with Delta and propensity score–matched controls with Omicron variant infection from the National COVID-19 Database in Qatar. Primary outcome was disease severity, determined by hospital admission, admission to the intensive care unit (ICU), or mechanical ventilation within 14 days of diagnosis, or death within 28 days.

Results. Among 1735 cases with Delta variant infection between 1 June and 6 November 2021, and 32 635 cases with Omicron variant infection between 1 January and 15 January 2022, who did not have prior infection and were not vaccinated, we identified 985 propensity score–matched pairs. Among those who were Delta infected, 84.2% had mild, 15.7% had moderate, and 0.1% had severe/critical disease. Among those who were Omicron infected, 97.8% had mild, 2.2% had moderate, and none had severe/critical disease ($P < .001$). Omicron variant infection (vs Delta) was associated with significantly lower odds of moderate or severe/critical disease (adjusted odds ratio [AOR], 0.12; 95% confidence interval [CI], .07–.18). Those aged 6–11 and 12 to <18 years had lower odds of developing moderate or severe/critical disease compared with those younger than age 6 years (aOR, 0.47; 95% CI, .33–.66 for 6–11 year olds; aOR, 0.45; 95% CI, .21–.94 for 12 to <18 year olds).

Conclusions. Omicron variant infection in children/adolescents is associated with less severe disease than Delta variant infection as measured by hospitalization rates and need for ICU care or mechanical ventilation. Those 6 to <18 years of age also have less severe disease than those <6 years old.

Keywords. SARS-CoV-2; Omicron variant; Delta variant; children; outcomes.

The epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is constantly evolving, with regular emergence of new variants of concern (VOCs), with each VOC associated with unique transmission, infectiousness, tissue tropism, and virulence characteristics [1–5]. A recent VOC is the Omicron variant, which, at least in adults, appears to be more infectious, perhaps because of more immune evasion, than the previous variants but less likely to be associated with more severe or critical disease [6–8]. For reasons that are incompletely understood, children appear less likely to be infected with SARS-CoV-2 and have a lower case fatality rate compared with older age groups [9, 10].

However, serious complications may occur in children, especially those with chronic and underlying conditions. Rarely, a hyperinflammatory syndrome with multisystem involvement has been reported, associated with high hospitalization rates and the need for organ system support [11, 12]. Multiple vaccines for SARS-CoV-2 have now been authorized for use in children aged 5 years and older, and are highly effective in preventing infection, hospitalization, admission to an intensive care unit (ICU), mechanical ventilation, or death [13, 14]. The natural history and clinical outcomes of coronavirus disease 2019 (COVID-19) in children and adolescents remain insufficiently understood, and there is limited information available regarding the severity of disease caused by the Omicron variant compared with the previous variants. A recent study from the United States reported a higher rate of hospitalization in children and adolescents with the Omicron variant compared with the Delta variant, but a lower proportion of the hospitalized children and adolescents required ICU admission or mechanical ventilation [15]. We conducted this study to

Received 2 March 2022; editorial decision 4 April 2022; published online 11 April 2022

Correspondence: A. A. Butt, P.O. Box 3050, Hamad Medical Corporation, Doha, Qatar (aabutt@hamad.qa)

Clinical Infectious Diseases® 2022;75(1):e361–7

© The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

https://doi.org/10.1093/cid/ciac275

compare the clinical outcomes of patients younger than 18 years of age who were infected with the Omicron variant.

METHODS

Study Setting

The study was conducted in Qatar, which has high rates of testing and vaccination of the eligible population for SARS-CoV-2 [16]. Since the identification of the first patient with SARS-CoV-2 on February 27, 2020, Qatar has experienced 4 distinct waves, now attributed to the wild-type, Alpha, Beta, and Omicron variants [17–22]. It also experienced a prolonged low-incidence phase with the Delta variant [17–22]. The first case of Omicron variant infection in Qatar was identified in a traveler on November 24, 2021, and within 4 weeks, it became the predominant circulating variant [22]. Starting very early in the pandemic, Qatar also instituted an aggressive testing policy, which included testing of all persons with compatible symptoms, contacts of confirmed cases, returning travelers, and persons in frontline high-risk professions (eg, healthcare workers, school staff) and screening of certain high-risk groups. Real-time reverse-transcription quantitative polymerase chain reaction (RT-qPCR) was used to test for SARS-CoV-2 on nasopharyngeal swabs at 2 national laboratories at Hamad Medical Corporation and Sidra Medicine.

Study Participants

Using the national COVID-19 database in Qatar, which includes every PCR test performed in Qatar since the beginning of the pandemic [23–25], we identified children (0–<18 years) with Delta variant infection diagnosed between 1 June and 6 November 2021, and those with Omicron variant infection diagnosed between 1 January and 15 January 2022. We excluded those with prior documented infection and those who had received any SARS-CoV-2 vaccination. Among these, we propensity score–matched each Delta infection case with an Omicron infection case based on age, sex, nationality, and presence of comorbidities. We performed 1:1 matching, using the nearest neighbor matching with a caliper of 0.2 standard deviations.

Definitions

The primary outcome of interest was severity of COVID-19 disease in children and adolescents infected with the Delta variant compared with those infected with the Omicron variant. Disease severity was categorized into mild (RT-PCR confirmed infection not requiring hospitalization), moderate (requiring acute care hospitalization but no ICU admission or mechanical ventilation or death), and severe/critical (admission to an ICU, mechanical ventilation, or death). All outcomes within 14 days of the index positive test were included, except death, for which a 28-day period was included. All children with COVID-19 in Qatar requiring hospitalization are admitted to designated

public hospitals, thereby ensuring complete capture of all hospital admissions and subsequent inpatient care. Comorbidities were identified based on associated diagnostic codes in the electronic medical records, as used in our previous publications [26–28]. SARS-CoV-2 infection was confirmed from the national COVID-19 database [23–25]. Vaccination status was also confirmed from the national COVID-19 database, which contains a record of every SARS-CoV-2–vaccinated person in Qatar [23, 24].

Laboratory Methods and Classification by Variant Type

Nasopharyngeal and/or oropharyngeal swabs were collected for PCR testing and placed in universal transport medium. Aliquots of universal transport medium were: (1) extracted on a KingFisher Flex (Thermo Fisher Scientific, USA), MGISP-960 (MGI, China), or ExiPrep 96 Lite (Bioneer, South Korea) followed by testing with RT-qPCR using TaqPath COVID-19 Combo Kits (Thermo Fisher Scientific) on an ABI 7500 FAST (Thermo Fisher Scientific); (2) tested directly on the Cepheid GeneXpert system using the Xpert Xpress SARS-CoV-2 (Cepheid, USA); or (3) loaded directly into a Roche Cobas 6800 system and assayed with the Cobas SARS-CoV-2 Test (Roche, Switzerland). The first assay targets the viral S, N, and ORF1ab gene regions. The second targets the viral N and E gene regions, and the third targets the ORF1ab and E gene regions. All PCR testing was conducted at the Hamad Medical Corporation Central Laboratory or Sidra Medicine Laboratory following standardized protocols.

Surveillance for SARS-CoV-2 variants in Qatar is mainly based on viral genome sequencing and multiplex RT-qPCR variant screening [29] of random positive clinical samples [19–21, 23, 24, 30], complemented by deep sequencing of wastewater samples [30, 31]. Between 23 March 2021 and 18 November 2021 (before suspected introduction of the Omicron variant), RT-qPCR genotyping of 19 234 randomly collected SARS-CoV-2–positive specimens on a weekly basis identified 3494 (18.2%) Alpha (B.1.1.7)-like cases, 5768 (30.0%) Beta (B.1.351)-like cases, 9914 (51.5%) “other” variant cases, and 58 (0.3%) B.1.375-like or B.1.258-like cases [20, 22, 30]. The accuracy of the RT-qPCR genotyping was verified against either Sanger sequencing of the receptor-binding domain of SARS-CoV-2 surface glycoprotein (S) gene, or by viral whole-genome sequencing on a Nanopore GridION or MGI-G50 sequencing devices. From 236 random samples (27 Alpha-like, 186 Beta-like, and 23 “other” variants), PCR genotyping results for Alpha-like, Beta-like, and “other” variants were in 88.8% (23 of 27), 99.5% (185 of 186), and 100% (23 of 23) agreement with the SARS-CoV-2 lineages assigned by sequencing. Within the “other” variant category, Sanger sequencing and/or Illumina sequencing of the receptor-binding domain of SARS-CoV-2 spike gene on 728 random samples confirmed that 701 (96.3%) were Delta cases and 17 (2.3%)

were other variant cases, with 10 (1.4%) samples failing lineage assignment. Accordingly, a Delta case was proxied as any “other” case identified through the RT-qPCR based variant screening. All the variant RT-qPCR screening was conducted at the Sidra Medicine Laboratory following standardized protocols.

A total of 315 random SARS-CoV-2-positive specimens collected between 19 December 2021 and 22 January 2022, were viral whole-genome sequenced on an MGI-G50 sequencing device. Of these, 300 (95.2%) were confirmed as Omicron infections and 15 (4.8%) as Delta (B.1.617.2) infections [22, 30, 32, 33]. No Delta case was detected in the viral genome sequencing after 8 January 2022. The large Omicron-wave exponential-growth phase in Qatar started on 19 December 2021, and peaked in mid-January 2022 [22, 30, 33]. The study duration for Omicron coincided with the intense Omicron wave in which Delta incidence was very limited. Accordingly, any PCR-positive test between 1 January and 15 January 2022 was used as a proxy for Omicron infection.

Statistical Analyses

In our recent analysis of the adult population in Qatar, we found that 15.2% of those infected with the Delta variant and 1.5% of propensity score-matched persons infected with the Omicron variant had moderate disease requiring hospitalization within 14 days of the index positive SARS-CoV-2 test (Adeel Butt, unpublished data). Because children generally experience less severe disease, we assumed that the rate of hospitalization among those infected with the Delta variant would be one-half of what is experienced in adults. Based on a very conservative a priori assumption that a 50% reduction in rate of hospitalization in those infected with the Omicron variant constitutes a clinically significant difference, we calculated that a minimum sample size of 1182 persons (591 in the Delta group and 591 in the Omicron group) would detect this difference at an alpha level of .05 with a power of 80%.

We calculated and compared the proportions of persons with mild, moderate, or severe/critical disease among those infected with the Delta and the Omicron variants; 95% confidence intervals (CIs) were calculated to express the spread. Multivariable logistic regression was used to calculate the adjusted odds ratios (aORs) and 95% CIs for factors associated with these outcomes. Where *P* values were used for comparison, a *P* value <.05 was considered statistically significant. All analyses were done using IBM-SPSS version 27.0 (Armonk, NY, USA).

Ethical Review

Hamad Medical Corporation, Weill Cornell Medicine-Qatar, and Qatar University institutional review boards approved this study. A waiver of informed consent was granted because of the retrospective nature of data retrieval.

RESULTS

Among 1359 children and adolescents with Delta variant infection and 32 635 with Omicron variant infection during the study period, we identified 985 propensity score-matched pairs that were included in the final analysis (Figure 1). Among those with Delta variant infection, the median age was 7 years (interquartile range, 3–9), 54.6% were females, 39.5% were Qataris, and 85.7% had no comorbidities. Among those with Omicron variant infection, the median age was 6 years (interquartile range, 3–10), 52.2% were females, 36.8% were Qataris, and 85.6% had no comorbidities (Table 1). Individual comorbidities and the baseline characteristics of the entire study population before propensity score matching (1359 with Delta and 32 635 with Omicron variant infection) are also provided in Table 1.

Among children and adolescents with Delta variant infection, 84.2% had mild disease, 15.7% had moderate disease, and 0.1% had severe/critical disease. Among children with Omicron variant infection, 97.8% had mild disease, 2.2% had moderate disease, and none had severe/critical disease (Table 2). In multivariable logistic regression analysis, infection with the Omicron variant was associated with significantly lower odds of moderate or severe/critical disease compared with Delta variant infection (aOR, 0.12; 95% CI, .07–.18). Compared with children younger than 6 years old, those 6–11 years old and those 12 to <18 years old had lower odds of developing moderate or severe/critical disease (aOR, .47; 95% CI, .33–.66 for 6–11 year olds; aOR, 0.45; 95% CI, .21–.94 for 12 to <18 years old). Sex, nationality, and comorbidity count were not associated with the odds of developing moderate or severe/critical disease (Table 3).

We also conducted logistic regression analysis by disease severity stratified by the infecting variant (Table 4). For both Delta and Omicron variant infection, those aged 6–11 years had lower odds of developing moderate or severe/critical disease compared with those younger than 6 years old (aOR, 0.50; 95% CI, .34–.73 for Delta; aOR, 0.25; 95% CI, .09–.71 for Omicron). For those with Omicron variant infection, the presence of 1 or more comorbidity was associated with higher odds of developing moderate or severe/critical disease (aOR, 3.16; 95% CI, 1.11–9.00). This association was not significant among those with Delta variant infection (Table 4).

DISCUSSION

In this large national study, we describe the severity of COVID-19 disease in children infected with the Omicron variant compared with children infected with the Delta variant. We found the COVID-19 disease from the Omicron variant to be significantly less severe than disease from the Delta variant.




Figure 1. Study flow sheet. *Propensity score matching done on age, sex, nationality, and comorbidities; nearest neighbor matching with caliper of 0.2 standard deviations.

We recently demonstrated that adults infected with the Omicron variant are 10-fold less likely to develop moderate or severe/critical disease compared with those infected with the Delta variant (Adeel Butt, unpublished data). Our current results mirror those results with a nearly 8-fold lower rate of moderate or severe/critical disease in children infected with the Omicron variant. Although a direct comparison cannot be made, the proportion of adults with moderate and severe disease because of the Omicron and Delta variants was remarkably similar to what we found in children with disease from the same variant. The reasons for this are not known. Increasing age and presence of comorbidities are associated with more severe disease in the adult population, and it is intuitive to assume that children and adolescents with inherently lesser comorbidities would experience significantly less severe disease outcomes. It is possible that the threshold for admission was lower in children and adolescents, which is the definition of moderate disease. However, criteria for mechanical ventilation are not likely to be much different, with such interventions executed only in those with severe or critical disease.

Within children and adolescents, those who were 6–11 years old were less likely to have moderate or severe/critical disease compared with those younger than 6 years old. Whether this is due to a poorer immune response or other reasons such as

the anatomy of the upper respiratory tract in small children is not clear. As mentioned earlier, another possibility is the lower threshold for admitting younger patients compared with older individuals with the same severity of symptoms. If the safety and efficacy of the current vaccines are confirmed in children younger than 6 years old, these data provide supporting evidence to extend the vaccination to this age group.

We noted that the presence of comorbidities was associated with moderate or severe outcomes among those with the Omicron variant infection but not with the Delta variant infection. The reason(s) for this are unclear. A potential explanation of this finding is that Omicron may affect the respiratory tract differentially and selectively compared with the Delta variant in children and adolescents. Approximately 14% of the individuals in each group had at least 1 comorbidity, and only a single individual in either group had more than 1 comorbidity. Among the 14% with at least 1 comorbidity, all but 1 had only 1 comorbidity, and 98% of those were chronic lung disease (including chronic asthma). Although we excluded all those with previous SARS-CoV-2 infection, some may have had undiagnosed infection, which may have induced immunity in 1 group. Vaccine-induced immunity is lower against the Omicron variant compared with the Delta variant. Whether this is true for natural immunity after infection is unknown.

Table 1. Baseline Characteristics of Propensity Score-Matched Persons Infected With the Delta and Beta Variants

	Before Matching			After Propensity Score Matching		
	Delta Variant Infection N = 1359	Omicron Variant Infection N = 32 635	SMD ^a	Delta Variant Infection N = 985	Omicron Variant Infection N = 985	SMD ^a
	N (%)	N (%)		N (%)	N (%)	
Age; median (IQR)	8 (5–11)	6 (3–10)	0.269	7 (3–9)	6 (3–10)	0.104
Age, y						
0–5	424 (31.2)	14 068 (43.1)	0.253	424 (43)	460 (46.7)	0.082
6–11	708 (52.1)	14 529 (44.5)		485 (49.2)	445 (45.2)	
12–17	227 (16.7)	4038 (12.4)		76 (7.7)	80 (8.1)	
Sex						
Female	620 (45.6)	15 728 (48.2)	0.052	538 (54.6)	514 (52.2)	0.049
Male	739 (54.4)	16 907 (51.8)		447 (45.4)	471 (47.8)	
Nationality						
Qatari	761 (56.0)	13 703 (42.0)	0.320	389 (39.5)	362 (36.8)	0.151
Southeast Asian	115 (8.5)	5328 (16.3)		115 (11.7)	167 (17)	
Other	483 (35.5)	13 604 (41.7)		481 (48.8)	456 (46.3)	
Comorbidities ^b						
Hypertension	1 (0.1)	22 (0.1)	0.002	1 (0.1)	0 (0)	0.045
Diabetes	3 (0.2)	43 (0.1)	0.021	0 (0)	0 (0)	N/A
Chronic lung disease ^c	236 (17.4)	4821 (14.8)	0.071	138 (14.0)	140 (14.2)	0.006
Cardiovascular disease	3 (0.2)	111 (0.3)	0.023	3 (0.3)	2 (0.2)	0.020
Chronic kidney disease	0 (0.0)	3 (0.0)	0.014	0 (0)	1 (0.1)	0.045
Chronic liver disease	0 (0.0)	2 (0.0)	0.011	0 (0)	0 (0)	N/A
Cancer	0 (0.0)	2 (0.0)	0.011	0 (0)	0 (0)	N/A
Comorbidity count						
0 comorbidities	1118 (82.3)	27 696 (84.9)	0.072	844 (85.7)	843 (85.6)	0.003
1 comorbidity	239 (17.6)	4879 (15.0)		140 (14.2)	141 (14.3)	
2+ comorbidities	2 (0.1)	60 (0.2)		1 (0.1)	1 (0.1)	

Abbreviations: IQR, interquartile range; N/A, not available; SMD, standardized mean difference.

^aA value of <0.1 suggests good matching.^bThere were no cases of autoimmune disease, chronic kidney disease, cancer, or cerebrovascular disease in any group.^cIncluding asthma.

Strengths of our study include a large national population, extensive testing, and uniform data collection methods. All children and adolescents requiring inpatient care were admitted to designated facilities, providing a high degree of

Table 2. Summary of Disease Outcomes of the 2 SARS-CoV-2 Variant Groups

	Delta Variant Infection N = 985 N (%)	Omicron Variant Infection N = 985 N (%)	P
Disease severity ^a			
Mild/not hospitalized	829 (84.2)	963 (97.8)	<.001
Moderate disease	155 (15.7)	22 (2.2)	
Critical disease	1 (0.1)	0 (0.0)	
Moderate or severe outcome	156 (15.8)	22 (2.2)	<.001

Abbreviations: ICU, intensive care unit; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

^aMild: infection confirmed but no hospitalization; moderate: hospitalized but no ICU admission or mechanical ventilation or death; severe/critical: mechanical ventilation OR ICU admission OR death.**Table 3. Multivariable Logistic Regression With Outcome Disease Status as Dependent Variable**

	Moderate or Severe/ Critical Outcome ^a		Moderate Disease ^a	
	aOR (95% CI)	P	aOR (95% CI)	P
Omicron variant (comparator: Delta variant)	0.12 (.07–.18)	<.001	0.12 (.07–.19)	<.001
Age (comparator: 0–5 y)				
6–11 y	0.47 (.33–.66)	<.001	0.47 (.33–.67)	<.001
12–17 y	0.45 (.21–.94)	.034	0.45 (.22–.94)	<.034
Male (comparator: female)	1.03 (.74–1.44)	.850	1.02 (.73–1.43)	.909
Nationality (comparator: Qatari)				
Southeast Asian	0.88 (.52–1.49)	.632	0.89 (.52–1.52)	.669
Other nationalities	0.84 (.58–1.21)	.350	0.85 (.59–1.23)	.391
Comorbidities count (comparator: 0)				
1+	1.01 (.63–1.61)	.977	1.02 (.64–1.62)	.942

Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; ICU, intensive care unit.

^aModerate: hospitalized but no ICU admission or mechanical ventilation; severe/critical: mechanical ventilation OR ICU admission OR death. There was only 1 case of severe/critical disease.

Table 4. Multivariable Logistic Regression With Outcome Disease Status as Dependent Variable, Stratified by Variant

	Moderate or Severe Outcome ^a			Moderate Disease ^a		
	Delta aOR (95% CI)	Omicron aOR (95% CI)	P*	Delta aOR (95% CI)	Omicron aOR (95% CI)	P*
Age (comparator: 0–5 y)						
6–11 y	0.50 (.34–.73)	0.25 (.09–.71)	.340	0.50 (.34–.73)	0.25 (.09–.71)	.340
12–17 y	0.55 (.25–1.18)	N/A	N/A	0.55 (.26–1.18)	N/A	N/A
Male (comparator: female)						
	0.94 (.65–1.35)	1.75 (.69–4.42)	.078	0.93 (.64–1.33)	1.75 (.69–4.42)	.073
Nationality (comparator: Qatari)						
Southeast Asian	0.78 (.42–1.41)	1.36 (.42–4.45)	.477	0.79 (.43–1.44)	1.36 (.42–4.45)	.488
Other nationalities	0.80 (.54–1.19)	1.05 (.39–2.84)	.881	0.81 (.54–1.21)	1.05 (.39–2.84)	.901
Comorbidities count (comparator: 0)						
1 or more comorbidity	0.82 (.048–1.38)	3.16 (1.11–9.00)	.033	0.83 (.49–1.39)	3.16 (1.11–9.00)	.034

Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; ICU, intensive care unit; N/A, not available.

^aModerate: hospitalized but no ICU admission or mechanical ventilation; severe/critical: mechanical ventilation OR ICU admission OR death.

* P-value comparing odds ratios between Delta and Omicron variants.

uniformity in admission criteria and subsequent care, including decisions to transfer to an ICU setting and initiation of mechanical ventilation. Certain limitations also need to be noted. This was a retrospective study, and despite propensity score matching, the possibility of residual confounding cannot be excluded. Although the study excluded persons with a documented prior infection, some of the prior infections may have not been documented. With Omicron cases being diagnosed several weeks after Delta cases, it is possible that some of the observed lower severity of Omicron infections could be due to a higher level of accrued natural immunity. However, this may only explain a small part of the lower severity of Omicron infections because the infection diagnosis rate is high in the pediatric population in Qatar as a consequence of the high testing rates.

In conclusion, infection with the Omicron variant in children and adolescents is associated with significantly lower severity of infection as measured by hospitalization rates and need for ICU care or mechanical ventilation. This is reassuring considering the large number of children and adolescents infected during the Omicron wave across the globe.

Notes

Author contributions. Concept and study design: A. A. B., L. J. A. Drafting of the manuscript: A. A. B. Data acquisition: A. H. K., A. N. L., S. L., R. M. S., H. C. Data analysis: S. R. D., A. A. B., L. J. A. Data interpretation: A. A. B., S. R. D., L. J. A. Laboratory testing: P. V. C., P. T., M. R. H., H. M. Y., H. A. A., M. K. S. Critical appraisal and review: A. A. B., L. J. A., S. R. D., H. C., A. A. K., P. V. C., P. T., M. R. H., H. M. Y., H. A. A., M. K. S., M. A. A., A. Z., A. H. K., A. N. L., R. B., A. A. Final approval: A. A. B., L. J. A., S. R. D., H. C., A. A. K., P. V. C., P. T., M. R. H., H. M. Y., H. A. A., M. K. S., S. L., R. M. S., M. A. A., A. Z., A. H. K., A. N. L., R. B., A. A. A. B. and L. J. A.—R. had complete access to the data at all times and accept responsibility for the integrity of this article.

Acknowledgments. The authors are grateful for the leadership and assistance provided by the Ministry of Public Health in Qatar and the Business Intelligence Unit at Hamad Medical Corporation and for all the dedicated frontline healthcare workers who have selflessly served and provided care and comfort to all patients in Qatar.

Disclaimer. The views expressed in this article are those of the authors and do not necessarily represent official government views or policy of the State of Qatar or Hamad Medical Corporation.

Financial support. S. R. D., H. C., and L. J. A. are grateful for support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar.

Potential conflicts of interest. A. A. B. has received investigator-initiated grant funding from Gilead Sciences (to the institution, Veterans Health Foundation of Pittsburgh) that is unrelated to the work presented here. All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

- Butt AA, Dargham SR, Chemaitelly H, et al. Severity of illness in persons infected with the SARS-CoV-2 delta variant vs beta variant in Qatar. *JAMA Intern Med* 2022; 182:197–205.
- Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. *Lancet Infect Dis* 2022; 22:35–42.
- Liu Y, Rocklov J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. *J Travel Med* 2021; 28: taab124.
- Herlihy R, Bamberg W, Burakoff A, et al. Rapid increase in circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant—Mesa County, Colorado, April–June 2021. *MMWR Morb Mortal Wkly Rep* 2021; 70:1084–7.
- Ong SWX, Chiew CJ, Ang LW, et al. Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta). *Clin Infect Dis* 2021; doi:10.1093/cid/ciab721.
- Zhao H, Lu L, Peng Z, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. *Emerg Microbes Infect* 2022; 11:277–83.
- Espenhain L, Funk T, Overvad M, et al. Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021. *Euro Surveill* 2021; 26:2101146.
- Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. *Lancet* 2022; 399:437–46.
- CDC. CDC COVID data tracker. 2022. Available at: <https://covid.cdc.gov/covid-data-tracker/#datatracker-home>. Accessed 20 February 2022.
- Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. *JAMA Pediatr* 2020; 174:882–9.
- Son MBF, Murray N, Friedman K, et al. Multisystem inflammatory syndrome in children—initial therapy and outcomes. *N Engl J Med* 2021; 385:23–34.

12. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. *N Engl J Med* **2020**; 383:334–46.
13. Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of BNT162b2 vaccine against critical covid-19 in adolescents. *N Engl J Med* **2022**; 386:713–23.
14. Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 covid-19 vaccine in children 5 to 11 years of age. *N Engl J Med* **2022**; 386:35–46.
15. Marks KJ, Whitaker M, Anglin O, et al. Hospitalizations of children and adolescents with laboratory-confirmed COVID-19—COVID-NET, 14 states, July 2021–January 2022. *MMWR Morb Mortal Wkly Rep* **2022**; 71:271–8.
16. MOPH (Ministry of Public Health Qatar). COVID-19 Vaccination Program Data. 2021. Available at: <https://covid19.moph.gov.qa/EN/Pages/Vaccination-Program-Data.aspx>. Accessed 27 January 2022.
17. Al Kuwari HM, Abdul Rahim HF, Abu-Raddad LJ, et al. Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February–18 April 2020. *BMJ Open* **2020**; 10:e040428.
18. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. *Sci Rep* **2021**; 11:6233.
19. Benslimane FM, Al Khatib HA, Al-Jamal O, et al. One year of SARS-CoV-2: genomic characterization of COVID-19 outbreak in Qatar. *Front Cell Infect Microbiol* **2021**; 11:768883.
20. Hasan MR, Kalikiri MKR, Mirza F, et al. Real-time SARS-CoV-2 genotyping by high-throughput multiplex PCR reveals the epidemiology of the variants of concern in Qatar. *Int J Infect Dis* **2021**; 112:52–4.
21. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. *N Engl J Med* **2021**; 385:e83.
22. Altarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the Omicron variant from previous SARS-CoV-2 infection. *N Engl J Med* **2022**; 386:1288–90.
23. Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. *N Engl J Med* **2021**; 385:187–9.
24. Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nat Med* **2021**; 27:1614–21.
25. Butt AA, Nafady-Hego H, Chemaitelly H, et al. Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination. *Int J Infect Dis* **2021**; 110:353–8.
26. Butt AA, Azad AM, Kartha AB, Masoodi NA, Bertollini R, Abou-Samra AB. Volume and acuity of emergency department visits prior to and after COVID-19. *J Emerg Med* **2020**; 59:730–4.
27. Butt AA, Kartha A, Asaad N, Azad AM, Bertollini R, Abou-Samra AB. Impact of COVID-19 upon changes in emergency room visits with chest pain of possible cardiac origin. *BMC Res Notes* **2020**; 13:539.
28. Butt AA, Kartha AB, Masoodi NA, et al. Hospital admission rates, length of stay, and in-hospital mortality for common acute care conditions in COVID-19 vs. pre-COVID-19 era. *Public Health* **2020**; 189:6–11.
29. Vogels C, Fauver J, Grubaugh N. Multiplexed RT-qPCR to screen for SARS-COV-2 B.1.1.7, B.1.351, and P.1 variants of concern V.3. *Protocols.io* 2021; doi:10.17504/protocols.io.br9vm966.
30. GISAIID. National project of surveillance for variants of concern and viral genome sequencing. Qatar viral genome sequencing data. Data on randomly collected samples. 2022. Available at: <https://www.gisaid.org/phylogenetics/global/nextstrain/>. Accessed 4 April 2022.
31. Saththasivam J, El-Malah SS, Gomez TA, et al. COVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in Qatar. *Sci Total Environ* **2021**; 774:145608.
32. WHO. Tracking SARS-CoV-2 variants. 2022. Available at: <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>. Accessed 31 January 2022.
33. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar. *N Engl J Med* **2022**; doi:10.1056/NEJMoa2200797.